Exosome removal as a therapeutic adjuvant in cancer
Open Access
- 27 June 2012
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 134
Abstract
Exosome secretion is a notable feature of malignancy owing to the roles of these nanoparticles in cancer growth, immune suppression, tumor angiogenesis and therapeutic resistance. Exosomes are 30–100 nm membrane vesicles released by many cells types during normal physiological processes. Tumors aberrantly secrete large quantities of exosomes that transport oncoproteins and immune suppressive molecules to support tumor growth and metastasis. The role of exosomes in intercellular signaling is exemplified by human epidermal growth factor receptor type 2 (HER2) over-expressing breast cancer, where exosomes with the HER2 oncoprotein stimulate tumor growth and interfere with the activity of the therapeutic antibody Herceptin®. Since numerous observations from experimental model systems point toward an important clinical impact of exosomes in cancer, several pharmacological strategies have been proposed for targeting their malignant activities. We also propose a novel device strategy involving extracorporeal hemofiltration of exosomes from the entire circulatory system using an affinity plasmapheresis platform known as the Aethlon ADAPT™ (adaptive dialysis-like affinity platform technology) system, which would overcome the risks of toxicity and drug interactions posed by pharmacological approaches. This technology allows affinity agents, including exosome-binding lectins and antibodies, to be immobilized in the outer-capillary space of plasma filtration membranes that integrate into existing kidney dialysis systems. Device therapies that evolve from this platform allow rapid extracorporeal capture and selective retention of target particles < 200 nm from the entire circulatory system. This strategy is supported by clinical experience in hepatitis C virus-infected patients using an ADAPT™ device, the Hemopurifier®, to reduce the systemic load of virions having similar sizes and glycosylated surfaces as cancer exosomes. This review discusses the possible therapeutic approaches for targeting immune suppressive exosomes in cancer patients, and the anticipated significance of these strategies for reversing immune dysfunction and improving responses to standard of care treatments.Keywords
This publication has 141 references indexed in Scilit:
- Amphiregulin Exosomes Increase Cancer Cell InvasionCurrent Biology, 2011
- Induction of pregnancy during established EAE halts progression of CNS autoimmune injury via pregnancy-specific serum factorsJournal of Neuroimmunology, 2011
- B7‐1/2, but not PD‐L1/2 molecules, are required on IL‐10‐treated tolerogenic DC and DC‐derived exosomes for in vivo functionEuropean Journal of Immunology, 2009
- Induction of myeloid‐derived suppressor cells by tumor exosomesInternational Journal of Cancer, 2009
- Tumor‐derived microvesicles in sera of patients with head and neck cancer and their role in tumor progressionHead & Neck, 2009
- RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancerGynecologic Oncology, 2008
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicityBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Exosomes: endosomal-derived vesicles shipping extracellular messagesCurrent Opinion in Cell Biology, 2004